Want to see MCK full AI Analyst Report?
Operating Income by Segment
Reveals profitability across different business units, highlighting which segments drive earnings and where there may be opportunities or challenges.McKesson’s profitability profile is shifting: U.S. Pharmaceutical remains the cash engine, Prescription Technology shows steady margin expansion, and the newly reported Oncology & Multispecialty immediately delivers meaningful operating profit—validating the re‑segmentation and recent acquisitions highlighted on the call. Medical‑Surgical’s 2024 shortfall appears seasonal and operationally managed ahead of a potential IPO, but International is the wild card—large, infrequent charges drive quarter-to-quarter volatility and could offset underlying improvement, so watch for one‑time items when modeling future guidance.
Date | International | Other | U.S. Pharmaceutical | Prescription Technology Solutions | Medical-Surgical Solutions | Oncology & Multispecialty |
|---|---|---|---|---|---|---|
Jun 30, 2026 | $0.00 | $0.00 | $903.00M | $226.00M | $122.00M | $325.00M |
Mar 31, 2026 | $0.00 | $518.00M | $1.16B | $286.00M | $232.00M | $301.00M |
Dec 31, 2025 | $0.00 | $31.00M | $1.05B | $261.00M | $265.00M | $304.00M |
Sep 30, 2025 | $0.00 | $28.00M | $852.00M | $244.00M | $220.00M | $332.00M |
Jun 30, 2025 | $92.00M | $0.00 | $727.00M | $253.00M | $221.00M | $0.00 |
Mar 31, 2025 | $94.00M | $0.00 | $1.29B | $248.00M | $227.00M | $0.00 |
Dec 31, 2024 | $111.00M | $0.00 | $854.00M | $219.00M | $269.00M | $0.00 |
Sep 30, 2024 | -$508.00M | $0.00 | $1.07B | $205.00M | $89.00M | $0.00 |
Jun 30, 2024 | $90.00M | $0.00 | $781.00M | $203.00M | $188.00M | $0.00 |
Mar 31, 2024 | $70.00M | $0.00 | $1.06B | $188.00M | $213.00M | $0.00 |